119 related articles for article (PubMed ID: 32521854)
1. Postoperative expressions of TRACP5b and CA125 in patients with breast cancer and their values for monitoring bone metastasis.
Feng C; Zhan Y; Shao H; Wang Z; Zhu S
J BUON; 2020; 25(2):688-695. PubMed ID: 32521854
[TBL] [Abstract][Full Text] [Related]
2. Tartrate-resistant acid phosphatase 5b activity is a useful bone marker for monitoring bone metastases in breast cancer patients after treatment.
Chung YC; Ku CH; Chao TY; Yu JC; Chen MM; Lee SH
Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):424-8. PubMed ID: 16537696
[TBL] [Abstract][Full Text] [Related]
3. The semiquantitative bone scintigraphy index correlates with serum tartrate-resistant acid phosphatase activity in breast cancer patients with bone metastasis.
Tsai SH; Chen CY; Ku CH; Janckila AJ; Yam LT; Yu JC; Chuang KW; Chao TY
Mayo Clin Proc; 2007 Aug; 82(8):917-26. PubMed ID: 17673059
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic value of TRACP5b expression in patients with bone tumors.
Zhang Q; Cao L; Miao XD; Wu YP
J Biol Regul Homeost Agents; 2019; 33(2):557-562. PubMed ID: 30973000
[TBL] [Abstract][Full Text] [Related]
5. Tartrate-resistant acid phosphatase 5b is a useful serum marker for extensive bone metastasis in breast cancer patients.
Chao TY; Yu JC; Ku CH; Chen MM; Lee SH; Janckila AJ; Yam LT
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):544-50. PubMed ID: 15701839
[TBL] [Abstract][Full Text] [Related]
6. Serum tartrate-resistant acid phosphatase 5b (TRACP5b) activity as a biomarker for bone metastasis in non-small cell lung cancer patients.
Yao NS; Wu YY; Janckila AJ; Ku CH; Hsieh AT; Ho CL; Lee SH; Chao TY
Clin Chim Acta; 2011 Jan; 412(1-2):181-5. PubMed ID: 20932965
[TBL] [Abstract][Full Text] [Related]
7. Serum Levels of NTx and TRACP5b in Giant Cell Tumor of Bone and its Clinical Implications.
Chen J; Younusi A; Cao L; Xu L; Zhou Y; Zhen T; Song X
Clin Lab; 2015; 61(8):1077-81. PubMed ID: 26427154
[TBL] [Abstract][Full Text] [Related]
8. Expression and significance of ER, PR, VEGF, CA15-3, CA125 and CEA in judging the prognosis of breast cancer.
Zhang SJ; Hu Y; Qian HL; Jiao SC; Liu ZF; Tao HT; Han L
Asian Pac J Cancer Prev; 2013; 14(6):3937-40. PubMed ID: 23886210
[TBL] [Abstract][Full Text] [Related]
9. Bone turnover markers in women with early stage breast cancer who developed bone metastases. A prospective study with multivariate logistic regression analysis of accuracy.
Lumachi F; Basso SM; Camozzi V; Tozzoli R; Spaziante R; Ermani M
Clin Chim Acta; 2016 Sep; 460():227-30. PubMed ID: 27404457
[TBL] [Abstract][Full Text] [Related]
10. Potential risk factors of ovarian cancer and analysis of CA125, a biomarker used for its monitoring and diagnosis.
Mansha M; Gill A; Thomson PC
Mol Biol Rep; 2019 Jun; 46(3):3325-3332. PubMed ID: 31006098
[TBL] [Abstract][Full Text] [Related]
11. Better Predictive Value of Cancer Antigen125 (CA125) as Biomarker in Ovary and Breast Tumors and its Correlation with the Histopathological Type/Grade of the Disease.
Nazmeen A; Maiti S; Mandal K; Roy SK; Ghosh TK; Sinha NK; Mandal K
Med Chem; 2017; 13(8):796-804. PubMed ID: 28440189
[TBL] [Abstract][Full Text] [Related]
12. Detection of Bone Metastases in Breast Cancer (BC) Patients by Serum Tartrate-Resistant Acid Phosphatase 5b (TRACP 5b), a Bone Resorption Marker and Serum Alkaline Phosphatase (ALP), a Bone Formation Marker, in Lieu of Whole Body Skeletal Scintigraphy with Technetium99m MDP.
Sarvari BK; Sankara Mahadev D; Rupa S; Mastan SA
Indian J Clin Biochem; 2015 Jan; 30(1):66-71. PubMed ID: 25646043
[TBL] [Abstract][Full Text] [Related]
13. Association of circulating Progesterone Receptor Membrane Component-1 (PGRMC1) with breast tumor characteristics and comparison with known tumor markers.
Ruan X; Cai G; Wei Y; Gu M; Zhang Y; Zhao Y; Mueck AO
Menopause; 2020 Feb; 27(2):183-193. PubMed ID: 31876619
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
[TBL] [Abstract][Full Text] [Related]
15. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
[TBL] [Abstract][Full Text] [Related]
16. Biological sources of variations of tartrate-resistant acid phosphatase 5b in a healthy Japanese population.
Kikuchi W; Ichihara K; Mori K; Shimizu Y
Ann Clin Biochem; 2021 Jul; 58(4):358-367. PubMed ID: 33715446
[TBL] [Abstract][Full Text] [Related]
17. [Prognostic value of new TNM staging and serum CA125 in malignant peritoneal mesothelioma].
Wei F; Zheng GQ; Song H; Liang YF; Yin WJ; Sun NN; Yang YX
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2020 May; 38(5):321-326. PubMed ID: 32536066
[No Abstract] [Full Text] [Related]
18. Tartrate-resistant acid phosphatase 5b as a serum marker of bone metastasis in breast cancer patients.
Chao TY; Ho CL; Lee SH; Chen MM; Janckila A; Yam LT
J Biomed Sci; 2004; 11(4):511-6. PubMed ID: 15153786
[TBL] [Abstract][Full Text] [Related]
19. Bone metastasis from breast cancer involves elevated IL-11 expression and the gp130/STAT3 pathway.
Ren L; Wang X; Dong Z; Liu J; Zhang S
Med Oncol; 2013; 30(3):634. PubMed ID: 23813018
[TBL] [Abstract][Full Text] [Related]
20. Age-related changes of serum tartrate-resistant acid phosphatase 5b and the relationship with bone mineral density in Chinese women.
Qin YJ; Zhang ZL; Zhang H; Hu WW; Liu YJ; Hu YQ; Li M; Gu JM; He JW
Acta Pharmacol Sin; 2008 Dec; 29(12):1493-8. PubMed ID: 19026169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
